Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-04-02 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
关于回购股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is titled '关于回购股份的进展公告' which translates to 'Announcement on the Progress of Share Repurchase'. It details the company's plan and progress regarding the repurchase of its own shares, including the amount, price limits, and regulatory compliance. It explicitly states the progress of the share repurchase as of a certain date and references previous announcements about the repurchase plan. The content is focused on the update of the share buyback activity rather than a full financial report or earnings release. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length is short and it is an announcement of progress, not a full report or financial statement. Therefore, the correct classification is POS with high confidence.
2024-04-02 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 Annual Report" of 烟台正海生物科技股份有限公司 (Yantai Zhenghai Bio-Tech Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data for the full fiscal year 2023, management discussion and analysis, governance, social responsibility, and financial statements. The document includes audited financial data, management's discussion of business and financial performance, risk factors, and other comprehensive disclosures. The length of the document (15,000 characters) and the presence of full financial and operational details confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-01 Chinese
2023年度独立董事述职报告（张兰丁）
Board/Management Information Classification · 95% confidence The document is titled '独立董事述职报告' which translates to 'Independent Director's Work Report' for the year 2023. It details the independent director's duties, attendance at board meetings, opinions on various board resolutions, communication with auditors, and oversight activities. The content focuses on the independent director's role, responsibilities, and evaluation of company governance and internal controls during the year. It does not contain financial statements or quarterly/annual financial results, nor is it an announcement or proxy material. This type of report is a management or board-related report focusing on governance and oversight by an independent director, fitting best under Board/Management Information (MANG). The document length is 4104 characters, which is relatively short but contains substantive content about board activities and director duties, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-01 Chinese
关于注销全资子公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the cancellation (注销) of a wholly-owned subsidiary by the company 烟台正海生物科技股份有限公司. It includes details about the subsidiary, financial data, the board meeting resolution, and the impact of the cancellation on the company. The document is short (1189 characters) and is a formal announcement of a corporate action rather than a detailed financial report or audit. It does not contain comprehensive financial statements or detailed management discussion. It is not a report publication announcement since it contains substantive information about the cancellation decision and financial impact. This fits best under Regulatory Filings (RNS) as a general regulatory announcement about corporate structure changes that do not fit other specific categories like MANG (management changes) or CAP (capital changes).
2024-04-01 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed evaluation and assurance of the company's internal control effectiveness related to financial reporting as of December 31, 2023. It references the responsibilities of management and the registered accountants, the scope of internal control evaluation, and the absence of significant internal control deficiencies. The document is a standalone audit-related assurance report on internal controls, not a full annual or interim financial report. It does not contain quarterly or annual financial statements but focuses on internal control effectiveness and related audit opinions. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and internal control attestations. The document length (9091 characters) and content confirm it is the report itself, not merely an announcement or certification letter. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-01 Chinese
独立董事提名人声明与承诺（李江华）
Board/Management Information Classification · 95% confidence The document is a detailed statement and commitment by a nominee for an independent director position at a listed company. It includes declarations about qualifications, compliance with laws and regulations, and independence criteria. There is no financial data, no report of financial performance, no voting results, no management changes, no earnings information, and no mention of any report publication. The content is focused on governance and compliance related to board nominations. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to changes or nominations in the company's board of directors.
2024-04-01 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.